ICU Acquired Weakness Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Intravenous FDY-5301 for the Prevention and Treatment of ICU Acquired Weakness in Major Trauma Patients.
Verified date | June 2023 |
Source | Faraday Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)
Status | Terminated |
Enrollment | 8 |
Est. completion date | March 4, 2022 |
Est. primary completion date | March 4, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age 18-75 years 2. Major trauma defined as: 1. thoracic and/or abdominal and/or pelvic injury 2. necessitating admission to ICU with ventilation anticipated for at least 24 hrs 3. hemorrhagic shock defined as systolic blood pressure (SBP) <90 mmHG requiring blood transfusion or base deficit of at least 6mEq/L pre-hospital arrival or within one hour after hospital arrival 3. IRB/IEC-approved consent obtained within 48 hours of first hospital arrival time (i.e., in case of transfers, use time of arrival to first hospital immediately post injury) Exclusion Criteria: 1. Likely to die within 48 hrs from time of screening 2. Any neurological condition that is perceived at the time of hospital admission as an immediate threat to life or incompatible with good functional recovery and where early limitation or withdrawal of therapy is being considered. For example: a. Computed tomography imaging showing evidence of traumatic brain injury (TBI), combined with best representative Glasgow Coma Score (GCS) Motor Score of =4 at approximately 24 hrs post injury 3. Evidence of nonreversible spinal cord injury 4. Bilateral femoral fractures 5. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative serum pregnancy test prior to randomization. 6. Known thyroid disease or thyroid disorder, including subjects on thyroid hormone replacement therapy at the time of randomization 7. Known allergy to iodine 8. Chronic renal disease requiring dialysis 9. Body mass index (BMI) >40 kg/m2 or <16 kg/m2 10. Body weight (BW) >140 kg (or >309 lb) 11. History or presence of debilitating neurologic or other neuromuscular disease (e.g., spina bifida, amyotrophic lateral sclerosis, multiple sclerosis) at time of randomization 12. Current metastatic cancer 13. Solid organ transplant recipient 14. Evidence of pre-existing sarcopenia defined as having a pre-trauma Clinical Frailty Score (CFS) of =5 or based on clinical judgement (e.g. frail by appearance, cachexia, etc.) 15. Use of systemic corticosteroids, immunomodulators, or oncologic chemotherapy within 6 months of randomization (inhaled and topical steroids are allowed) 16. Use of investigational drugs or devices within 30 days of randomization 17. Any clinically significant abnormality identified prior to randomization that in the judgment of the Investigator or Sponsor would preclude safe completion of the study, or confound the anticipated benefit of FDY-5301 |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital, Harvard Medical School | Boston | Massachusetts |
United States | The Ohio State University Wexner Medical Center | Columbus | Ohio |
United States | University of Florida Health Shands Hospital | Gainesville | Florida |
United States | Harborview | Seattle | Washington |
United States | Harbor-UCLA Medical Center | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Faraday Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Chelsea Critical Care Physical Assessment Tool | Chelsea Critical Care Physical Assessment Tool (CPAx) total score at Day 10, or hospital discharge, whichever occurs first. The Chelsea Critical Care Physical Assessment Tool components will be graded on a 6-point scale from dependent to independent (0 to 5). The individual values will be collated giving a total score out of 50. A higher score indicates a better outcome. | Day 10 or hospital discharge, whichever occurs first. | |
Primary | Organ Dysfunction Total Time to Recovery | Organ dysfunction total time to recovery (TTR) until Day 28 | Day 28 or hospital discharge, whichever occurs first. | |
Secondary | Medical Research Council Sum Score | Medical Research Council Sum Score (MRC-SS) at Day 28, or hospital discharge, whichever occurs first. The Medical Research Council Sum Score measures global peripheral muscle strength which ranges from 0 (complete paralysis) to 60 (normal strength). A higher score indicates a better outcome. | Day 28, or hospital discharge, whichever occurs first | |
Secondary | Sequential Organ Failure Assessment Score | The Sequential Organ Failure Assessment (SOFA) is a scoring system that assesses the performance of several organ systems in the body and assigns a score based on the data obtained in each category, this is scored during the ICU stay. The full-length Sequential Organ Failure Assessment score ranges from 0 to 24. A higher score indicates a worse outcome. | ICU hospital stay until Day 28 or ICU discharge if earlier | |
Secondary | Overall Survival at Day 28 | Confirmation of survival status will be obtained by speaking directly with subject, via medical records, or public health records. | Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05527678 -
5 Years Quality of Life and Early Mobilization in ICU
|
||
Recruiting |
NCT05537298 -
Muscle Recovery After Critical Illness
|
||
Completed |
NCT05473546 -
Diarrhea and Stipsis in Critically Ill Patients (NUTRITI)
|
||
Not yet recruiting |
NCT05326633 -
Effect of Protein, Mobility Therapy and Electric Stimulation on Recovery in Older ICU Survivors
|
Early Phase 1 | |
Not yet recruiting |
NCT06025760 -
Evaluation of Diaphragmatic Function and Quadriceps Muscle Thickness in Patients Receiving High Protein Nutrition
|
N/A | |
Completed |
NCT05048953 -
The Use of Musculoskeletal Ultrasound for the Detection of ICU-Acquired Weakness
|
||
Terminated |
NCT04095533 -
ICU Associated Weakness and Bedside Ultrasound Assessment
|
||
Terminated |
NCT04160039 -
Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit
|
N/A | |
Active, not recruiting |
NCT04944537 -
Current Situation and Analysis of ICU Management for Severe Trauma Patients in China
|
||
Recruiting |
NCT05865314 -
Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial)
|
N/A | |
Completed |
NCT04810273 -
Effect of Progressive Early Mobilization in Patients With TBI
|
N/A | |
Completed |
NCT04396197 -
Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care
|
||
Recruiting |
NCT04932330 -
Risk Factors of ICU-acquired Weakness
|
||
Completed |
NCT05008562 -
How COVID-19 Effects to Muscle Mass Change ın ICU?
|
||
Recruiting |
NCT05919940 -
Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )
|
N/A | |
Recruiting |
NCT04565002 -
Transcutaneous Electrical Diaphragmatic Stimulation in Critically Ill Elderly Patients
|
N/A | |
Recruiting |
NCT05396066 -
Respiratory and Quadriceps Muscle Fatigability After an ICU Acquired Weakness
|
||
Recruiting |
NCT04998643 -
Muscle Catabolism and Outcomes in Children Following Cardiac Surgery
|
||
Not yet recruiting |
NCT06184945 -
Behavioral Economic & Staffing Strategies in the ICU
|
N/A | |
Completed |
NCT03550222 -
Muscle Evaluation Using Ultrasound in the Critically Ill
|